- Home
- NHS vs SOPH Comparison
NHS vs SOPH Comparison
Compare NHS & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- SOPH
- Stock Information
- Founded
- NHS 2003
- SOPH 2011
- Country
- NHS United States
- SOPH Switzerland
- Employees
- NHS N/A
- SOPH N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NHS Finance
- SOPH Health Care
- Exchange
- NHS Nasdaq
- SOPH Nasdaq
- Market Cap
- NHS 221.6M
- SOPH 206.6M
- IPO Year
- NHS N/A
- SOPH 2021
- Fundamental
- Price
- NHS $7.70
- SOPH $3.12
- Analyst Decision
- NHS
- SOPH Strong Buy
- Analyst Count
- NHS 0
- SOPH 2
- Target Price
- NHS N/A
- SOPH $6.50
- AVG Volume (30 Days)
- NHS 111.8K
- SOPH 26.0K
- Earning Date
- NHS 01-01-0001
- SOPH 05-06-2025
- Dividend Yield
- NHS 13.44%
- SOPH N/A
- EPS Growth
- NHS N/A
- SOPH N/A
- EPS
- NHS N/A
- SOPH N/A
- Revenue
- NHS N/A
- SOPH $67,173,000.00
- Revenue This Year
- NHS N/A
- SOPH $14.86
- Revenue Next Year
- NHS N/A
- SOPH $22.76
- P/E Ratio
- NHS N/A
- SOPH N/A
- Revenue Growth
- NHS N/A
- SOPH 4.66
- 52 Week Low
- NHS $6.95
- SOPH $2.58
- 52 Week High
- NHS $9.17
- SOPH $6.28
- Technical
- Relative Strength Index (RSI)
- NHS 59.96
- SOPH 52.56
- Support Level
- NHS $7.53
- SOPH $2.85
- Resistance Level
- NHS $7.64
- SOPH $3.26
- Average True Range (ATR)
- NHS 0.09
- SOPH 0.20
- MACD
- NHS 0.02
- SOPH 0.02
- Stochastic Oscillator
- NHS 90.74
- SOPH 41.54
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.